Basal cell carcinoma

  • 1  Levell NJ, Igali L, Wright KA, Greenberg DC. Basal cell carcinoma epidemiology in the UK: the elephant in the room. Clin Exp Dermatol 2013;38:3679.Cross Ref linkPubmed link
  • 2  de Vries E, Micallef R, Brewster DH, et al. Population‐based estimates of the occurrence of multiple vs first primary basal cell carcinomas in 4 European regions. Arch Dermatol 2012;148:34754.Cross Ref linkPubmed link
  • 3  Silverberg E, Boring CC, Squires TS. Cancer statistics 1990. CA Cancer J Clin 1990;40:926.Cross Ref linkPubmed link
  • 4  Cakir , Adamson P, Cingi C. Epidemiology and economic burden of nonmelanoma skin cancer. Facial Plast Surg Clin North Am 2012;20:41922.Cross Ref linkPubmed link
  • 5  Goodwin RG, Holme SA, Roberts DL. Variations in registration of skin cancer in the United Kingdom. Clin Exp Dermatol 2004;29:32830.Cross Ref linkPubmed link
  • 6  Cancer Research UK. http://www.cancerresearchuk.org/cancer‐info/cancerstats/types/skin/incidence/uk‐skin‐cancer‐incidence‐statistics#nmsc (last accessed April 2015).
  • 7  National Cancer Intelligence Network (NCIN). Non‐melanoma Skin Cancer in England, Scotland, Northern Ireland, and Ireland. London: NCIN, 2013.
  • 8  National Cancer Intelligence Network (NCIN) Data Briefing. The Importance of Skin Cancer Registration. London: NCIN, 2010.
  • 9  Flohil SC, Seubring I, van Rossum MM, Coebergh JW, de Vries E, Nijsten T. Trends in Basal cell carcinoma incidence rates: a 37‐year Dutch observational study. J Invest Dermatol 2013;133:91318.Cross Ref linkPubmed link
  • 10  Eisemann N, Waldmann A, Geller AC, et al. Non‐melanoma skin cancer incidence and impact of skin cancer screening on incidence. J Invest Dermatol 2014;134:4350.Cross Ref linkPubmed link
  • 11  Lomas A, Leonardi‐Bee J, Bath‐Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012;166:106980.Cross Ref linkPubmed link
  • 12  Diffey BL, Langtry JA. Skin cancer incidence and the ageing population. Br J Dermatol 2005;153:67980.Cross Ref linkPubmed link
  • 13  Flohil SC, Koljenović S, de Haas ER, et al. Cumulative risks and rates of subsequent basal cell carcinomas in the Netherlands. Br J Dermatol 2011;165:87481.Cross Ref linkPubmed link
  • 14  Khalesi M, Whiteman DC, Tran B, et al. A meta‐analysis of pigmentary characteristics, sun sensitivity, freckling and melanocytic nevi and risk of basal cell carcinoma of the skin. Cancer Epidemiol 2013;37:53443.Cross Ref linkPubmed link
  • 15  Flohil SC, van der Leest RJ, Arends LR, de Vries E, Nijsten T. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta‐analysis. Eur J Cancer 2013;49:236575.Cross Ref linkPubmed link
  • 16  Stern RS. The mysteries of geographic variability in nonmelanoma skin cancer incidence. Arch Dermatol 1999;135:8434.Pubmed link
  • 17  Bauer A, Diepgen TL, Schmitt J. Is occupational solar ultraviolet irradiation a relevant risk factor for basal cell carcinoma? A systematic review and meta‐analysis of the epidemiological literature. Br J Dermatol 2011;165:61225.Pubmed link
  • 18  Kricker A, Armstrong BK, English DR, Heenan PJ. A dose–response curve for sun exposure and basal cell carcinoma. Int J Cancer 1995;60:4828.Cross Ref linkPubmed link
  • 19  Kricker A, Armstrong BK, English DR, Heenan PJ. Does intermittent sun exposure cause basal cell carcinoma? A case–control study in Western Australia. Int J Cancer 1995;60:48994.Cross Ref linkPubmed link
  • 20  Rosso S, Zanetti R, Martinez C, et al. The multicentre south European study ‘Helios’ II: different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer 1996;73:144754.Cross Ref linkPubmed link
  • 21  Madan V, Lear JT, Szeimies RM. Non‐melanoma skin cancer. Lancet 2010;375:67385.Cross Ref linkPubmed link
  • 22  Rünger TM. How different wavelengths of the ultraviolet spectrum contribute to skin carcinogenesis: the role of cellular damage responses. J Invest Dermatol 2007;127:21035.Cross Ref linkPubmed link
  • 23  Ridley AJ, Whiteside JR, McMillan TJ, Allinson SL. Cellular and sub‐cellular responses to UVA in relation to carcinogenesis. Int J Radiat Biol 2009;85:17795.Cross Ref linkPubmed link
  • 24  Lear JT, Smith AG, Strange RC, Fryer AA. Detoxifying enzyme genotypes and susceptibility to cutaneous malignancy. Br J Dermatol 2000;142:815.Cross Ref linkPubmed link
  • 25  Lear JT, Hoban P, Strange RC, Fryer AA. Basal cell carcinoma: from host response and polymorphic variants to tumour suppressor genes. Clin Exp Dermatol 2005;30:4955.Cross Ref linkPubmed link
  • 26  Jayaraman SS, Rayhan DJ, Hazany S, Kolodney MS. Mutational landscape of basal cell carcinomas by whole‐exome sequencing. J Invest Dermatol 2014;134:21320.Cross Ref linkPubmed link
  • 27  Stone DM, Hynes M, Armanini M, et al. The tumour‐suppressor gene patched encodes a candidate receptor for Sonic hedgehog. Nature 1996;384:12934.Cross Ref linkPubmed link
  • 28  Atwood SX, Li M, Lee A, Tang JY, Oro AE. GLI activation by atypical protein kinase C ι/λ regulates the growth of basal cell carcinomas. Nature 2013;494:4848.Cross Ref linkPubmed link
  • 29  Soufir N, Gerard B, Portela M, et al. PTCH mutations and deletions in patients with typical nevoid basal cell carcinoma syndrome and in patients with a suspected genetic predisposition to basal cell carcinoma: a French study. Br J Cancer 2006;95:54853.Cross Ref linkPubmed link
  • 30  Ali FR, Lear JT. Systemic treatments for basal cell carcinoma (BCC): the advent of dermato‐oncology in BCC. Br J Dermatol 2013;169:537.Cross Ref linkPubmed link
  • 31  Gudbjartsson DF, Sulem P, Stacey SN, et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet 2008;40:88691.Cross Ref linkPubmed link
  • 32  Brash DE. Roles of the transcription factor p53 in keratinocyte carcinomas. Br J Dermatol 2006;154 Suppl. 1:810.Cross Ref linkPubmed link
  • 33  Lear JT, Smith AG, Strange RC, Fryer AA. Detoxifying enzyme genotypes and susceptibility to cutaneous malignancy. Br J Dermatol 2000;142:815.Cross Ref linkPubmed link
  • 34  Ramachandran S, Lear JT, Ramsay H, et al. Presentation with multiple cutaneous basal cell carcinomas: association of glutathione S‐transferase and cytochrome P450 genotypes with clinical phenotype. Cancer Epidemiol Biomarkers Prev 1999;8:617.Pubmed link
  • 35  Saleh S, King‐Yin Lam A, Gertraud BP, et al. Telomerase activity of basal cell carcinoma in patients living in North Queensland, Australia. Hum Pathol 2007;38:10239.Cross Ref linkPubmed link
  • 36  Oh ST, Kim HS, Yoo NJ, Lee WS, Cho BK, Reichrath J. Increased immunoreactivity of membrane type‐1 matrix metalloproteinase (MT1‐MMP) and β‐catenin in high‐risk basal cell carcinoma. Br J Dermatol 2011;165:1197204.Cross Ref linkPubmed link
  • 37  Moloney FJ, Comber H, Conlon PJ, et al. The role of immunosuppression in the pathogenesis of basal cell carcinoma. Br J Dermatol 2006;154:7901.Cross Ref linkPubmed link
  • 38  Moloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM. A population‐based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006;154:498504.Cross Ref linkPubmed link
  • 39  Rangwala S, Tsai KY. Roles of the immune system in skin cancer. Br J Dermatol 2011;165:95365.Cross Ref linkPubmed link
  • 40  Mehrany K, Weenig RH, Pittelkow MR, et al. High recurrence rates of Basal cell carcinoma after Mohs surgery in patients with chronic lymphocytic leukemia. Arch Dermatol 2004;140:9858.Pubmed link
  • 41  Leonardi G, Vahter M, Clemens F, et al. Inorganic arsenic and basal cell carcinoma in areas of Hungary, Romania, and Slovakia: a case–control study. Environ Health Perspect 2012;120:7216.Cross Ref linkPubmed link
  • 42  Man I, Crombie IK, Dawe RS, Ibbotson SH, Ferguson J. The photocarcinogenic risk of narrowband UVB (TL‐01) phototherapy: early follow‐up data. Br J Dermatol 2005;152:7557.Cross Ref linkPubmed link
  • 43  Lichter MD, Karagas MR, Mott LA, et al. Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group. Arch Dermatol 2000;136:100711.
  • 44  Castori M, Morrone A, Kanitakis J, Grammatico P. Genetic skin diseases predisposing to basal cell carcinoma. Eur J Dermatol 2012;22:299309.Pubmed link
  • 45  Van Scott EJ, Reinertson RP. The modulating influence of stromal environment on epithelial cells studied in human autotransplants. J Invest Dermatol 1961;36:10917.Cross Ref linkPubmed link
  • 46  Weinstein GD, Frost P. Cell proliferation in human basal cell carcinoma. Cancer Res 1970;30:7248.Pubmed link
  • 47  Weedon D, Shand E. Amyloid in basal cell carcinomas. Br J Dermatol 1979;101:1416.Cross Ref linkPubmed link
  • 48  Madsen A. Studies on basal‐cell epithelioma of the skin: the architecture, manner of growth, and histogenesis of the tumours – whole tumours examined in serial sections cut parallel to the skin surface. Acta Pathol Microbiol Scand Suppl 1965;117:363.
  • 49  Sanderson KV. The architecture of basal‐cell carcinoma. Br J Dermatol 1961;73:45574.Cross Ref linkPubmed link
  • 50  Sherertz EF, Pollack SV, Jegasothy BV. Correlation of basal cell epithelioma aggressiveness with local inhibition of host lymphocyte response. Clin Res 1982;30:266 (Abstract).
  • 51  Plaza JA, Ortega PF, Bengana C, Stockman DL, Suster S. Immunolabeling pattern of podoplanin (d2‐40) may distinguish basal cell carcinomas from trichoepitheliomas: a clinicopathologic and immunohistochemical study of 49 cases. Am J Dermatopathol 2010;32:6837.Cross Ref linkPubmed link
  • 52  Tebcherani AJ, de Andrade HF Jr, Sotto MN. Diagnostic utility of immunohistochemistry in distinguishing trichoepithelioma and basal cell carcinoma: evaluation using tissue microarray samples. Mod Pathol 2012;25:134553.Cross Ref linkPubmed link
  • 53  Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol 2006;19 Suppl. 2:S12747.Cross Ref linkPubmed link
  • 54  Farmer ER, Helwig EB. Metastatic basal cell carcinoma: a clinicopathologic study of 17 cases. Cancer 1980;46:74857.Cross Ref linkPubmed link
  • 55  McCormack CJ, Kelly JW, Dorevitch AP. Differences in age and body site distribution of the histological subtypes of basal cell carcinoma: a possible indicator of differing causes. Arch Dermatol 1997;133:5936.Cross Ref linkPubmed link
  • 56  Ramachandran S, Fryer A, Smith A, et al. Cutaneous basal cell carcinomas. Cancer 2001;92:3548.Cross Ref linkPubmed link
  • 57  Sexton M, Jones DB, Maloney ME. Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol 1990;23:111826.Cross Ref linkPubmed link
  • 58  Rippey JJ. Why classify basal cell carcinomas? Histopathology 1998;32:3938.Cross Ref linkPubmed link
  • 59  Schwipper V. Invasive basal cell carcinoma of the head and neck (basalioma terebrans). Facial Plastic Surg 2011;27:25865.Cross Ref link
  • 60  Gormley LJDE, Hirsch P. Aggressive basal cell carcinoma of the scalp. Arch Dermatol 1978;114:7823.Cross Ref linkPubmed link
  • 61  Ting PT, Kasper R, Arlette AP. Metastatic basal cell carcinoma: report of two cases and literature review. J Cutan Med Surg 2005;9:1015.Cross Ref linkPubmed link
  • 62  Larson DL, Gillespie JJ, Parsons RW. Metastatic basal cell carcinoma of the lung. South Med J 1980;73:6479.Cross Ref linkPubmed link
  • 63  Presser SE, Taylor JR. Clinical diagnostic accuracy of basal cell carcinoma. J Am Acad Dermatol 1987;16:98890.Cross Ref linkPubmed link
  • 64  Roozeboom MH, Mosterd K, Winnepenninckx VJ, et al. Agreement between histological subtype on punch biopsy and surgical excision in primary basal cell carcinoma. J Eur Acad Dermatol Venereol 2013;27:8948.Cross Ref linkPubmed link
  • 65  Lallas A, Argenziano G, Zendri E, et al. Update on non‐melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monitoring. Exp Rev Anticancer Ther 2013;13:54158.Cross Ref link
  • 66  Ulrich M, Stockfleth E, Roewert‐Huber J, Astner S. Noninvasive diagnostic tools for nonmelanoma skin cancer. Br J Dermatol 2007;157 S2:568.Cross Ref linkPubmed link
  • 67  Boone MA, Norrenberg S, Jemec GB, Del Marmol V. Imaging of basal cell carcinoma by high‐definition optical coherence tomography: histomorphological correlation. A pilot study. Br J Dermatol 2012;167:85664.Cross Ref linkPubmed link
  • 68  Bennàssar A, Vilata A, Puig S, Malvehy. Validation of fluorescent confocal microscopy criteria and histopathological correlation for the diagnosis of basal cell carcinoma and most common subtypes. Br J Dermatol 2014;170:3605.Cross Ref linkPubmed link
  • 69  Telfer NR, Colver GB, Morton CA; British Association of Dermatologists. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008;159:3548.Cross Ref linkPubmed link
  • 70  Bath‐Hextall FJ, Perkins W, Bong J, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007;24;CD003412.
  • 71  Bath‐Hextall F, Leonardi‐Bee J, Somchand N, Webster A, Delitt J, Perkins W. Interventions for preventing non‐melanoma skin cancers in high‐risk groups. Cochrane Database Syst Rev 2007;4:CD005414.Pubmed link
  • 72  Dummer R, Urosevic M, Kempf W, et al. Imiquimod in basal cell carcinoma: how does it work? Br J Dermatol 2003;149 Suppl. 66:578.Cross Ref linkPubmed link
  • 73  Chitwood K, Etzkorn J, Cohen G. Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons. Dermatol Surg 2013;39:130616.Cross Ref linkPubmed link
  • 74  Eigentler TK, Kamin A, Weide BM, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low‐risk nodular basal cell carcinoma. J Am Acad Dermatol 2007;57:61621.Cross Ref linkPubmed link
  • 75  McKay KM, Sambrano BL, Fox PS, et al. Thickness of superficial basal cell carcinoma (sBCC) predicts imiquimod efficacy: a proposal for a thickness‐based definition of sBCC. Br J Dermatol 2013;169:54954.Cross Ref linkPubmed link
  • 76  Arits AH, Mosterd K, Essers BA, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal‐cell carcinoma: a single blind, non‐inferiority, randomised controlled trial. Lancet Oncol 2013;14:64754.Cross Ref linkPubmed link
  • 77  Sloan KB, Sherertz EF, McTiernan RG. The effect of 5‐fluorouracil on inhibition of epidermal DNA synthesis in vivo: a comparison of the effect of formulations and a prodrug of 5‐FU. Arch Dermatol Res 1990;282:4846.Cross Ref linkPubmed link
  • 78  Gross K, Kircik L, Kricorian G. 5% 5‐Fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg 2007;33:4339.Pubmed link
  • 79  Tucker SB, Polasek JW, Perri AJ, Goldsmith EA. Long‐term follow‐up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy. J Am Acad Dermatol 2006;54:10338.Cross Ref linkPubmed link
  • 80  Lear JT. Oral hedgehog pathway inhibitors for basal cell carcinoma. N Engl J Med 2012;366:22256.Cross Ref linkPubmed link
  • 81  Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal‐cell carcinoma. N Engl J Med 2012;366:21719.Cross Ref linkPubmed link
  • 82  Wolfe CM, Green WH, Cognetta AB Jr, et al. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient. Dermatol Surg 2012;38:18636.Cross Ref linkPubmed link
  • 83  Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol 1987;123:3404.Cross Ref linkPubmed link
  • 84  Walker P, Hill D. Surgical treatment of basal cell carcinomas using standard postoperative histological assessment. Australas J Dermatol 2006;47:112.Cross Ref linkPubmed link
  • 85  Rowe DE, Carroll RJ, Day CL Jr, et al. Long‐term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow‐up. J Dermatol Surg Oncol 1989;15:31528.Cross Ref linkPubmed link
  • 86  Blixt E, Nelsen D, Stratman E. Recurrence rates of aggressive histologic types of basal cell carcinoma after treatment with electrodesiccation and curettage alone. Dermatol Surg 2013;39:71925.Cross Ref linkPubmed link
  • 87  Thissen M, Nieman F, Ideler A, Berretty P, Neumann H. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg 2000;26:75964.Cross Ref linkPubmed link
  • 88  Childers BJ, Goldwyn RM, Ramos D, et al. Long‐term results of irradiation for basal cell carcinoma of the skin of the nose. Plast Reconstr Surg 1994;93:116973.Cross Ref linkPubmed link
  • 89  Caccialanza M, Piccinno R, Grammatica A. Radiotherapy of recurrent basal and squamous cell skin carcinomas: a study of 249 re‐treated carcinomas in 229 patients. Eur J Dermatol 2001;11:258.Pubmed link
  • 90  Veness MJ. The important role of radiotherapy in patients with non‐melanoma skin cancer and other cutaneous entities. J Med Imaging Radiat Oncol 2008;52:27886.Cross Ref linkPubmed link
  • 91  Avril M, Auperin A, Margulis A, et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer 1997;76:1006.Cross Ref linkPubmed link
  • 92  Kleinerman RA. Radiation‐sensitive genetically susceptible pediatric sub‐populations. Pediatr Radiol 2009;39:S2731.Cross Ref linkPubmed link
  • 93  Landthaler M, Hagspiel HJ, Braun‐Falco O. Late irradiation damage to the skin caused by soft X‐ray radiation therapy of cutaneous tumors. Arch Dermatol 1995;131:1826.Cross Ref linkPubmed link
  • 94  Campolmi P, Brazzini B, Urso C, et al. Superpulsed CO2 laser treatment of basal cell carcinoma with intraoperatory histopathologic and cytologic examination. Dermatol Surg 2002;28:90911.Pubmed link
  • 95  Humphreys TR, Malhotra R, Scharf MJ, et al. Treatment of superficial basal cell carcinoma and squamous cell carcinoma in situ with a high‐energy pulsed carbon dioxide laser. Arch Dermatol 1998;134:124752.Pubmed link
  • 96  Jung DS, Cho HH, Ko HC, et al. Recurrent basal cell carcinoma following ablative laser procedures. J Am Acad Dermatol 2011;64:7239.Cross Ref linkPubmed link
  • 97  Ballard CJ, Rivas MP, McLeod MP, et al. The pulsed dye laser for the treatment of basal cell carcinoma. Lasers Med Sci 2011;26:6414.Cross Ref linkPubmed link
  • 98  Karen JK, Gareau DS, Dusza SW, et al. Detection of BCCs in Mohs excisions with fluorescence confocal mosaicing microscopy. Br J Dermatol 2009;160:124250.Cross Ref linkPubmed link

Fibroepithelial basal cell carcinoma

  • 99  Bowen AR, LeBoit PE. Fibroepithelioma of Pinkus is a fenestrated trichoblastoma. Am J Dermatopathol 2005;27:14954.Cross Ref linkPubmed link
  • 100  Sellheyer K, Nelson P, Kutzner H. Fibroepithelioma of Pinkus is a true basal cell carcinoma developing in association with a newly identified tumour‐specific type of epidermal hyperplasia. Br J Dermatol 2012;166:8897.Cross Ref linkPubmed link
  • 101  Zalaudek I, Ferrara G, Broganelli P, et al. Dermoscopy patterns of fibroepithelioma of pinkus. Arch Dermatol 2006;142:131822.Pubmed link

Naevoid basal cell carcinoma syndrome

  • 102  Evans DG, Ladusans EJ, Rimmer S, et al. Complications of the naevoid basal cell carcinoma syndrome: results of a population‐based study. J Med Genet 1993;30:4604.Cross Ref linkPubmed link
  • 103  Lo Muzio L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis 2008;3:32.Pubmed link
  • 104  Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor‐prone syndromes: Estimates from a UK family genetic register service. Am J Med Genet A 2010;152:32732.Cross Ref link
  • 105  Gorlin RJ. Nevoid basal cell carcinoma syndrome. Dermatol Clin 1995;13(1):11325.Pubmed link
  • 106  Howell JB, Mehregan AH. Pursuit of the pits in the naevoid basal cell carcinoma syndrome. Arch Dermatol 1970;102:58697.Cross Ref linkPubmed link
  • 107  Holubar K, Matras H, Smalik AV. Multiple palmar basal cell epitheliomas in basal cell naevus syndrome. Arch Dermatol 1970;10:67982.Cross Ref link
  • 108  Howell JB, Freeman RG. Structure and significance of the pits and their tumours in the naevoid basal cell carcinoma syndrome. J Am Acad Dermatol 1980;2:22438.Cross Ref linkPubmed link
  • 109  Mason JK, Helwig EB, Graham JH. Pathology of the naevoid basal cell carcinoma syndrome. Arch Pathol 1965;79:4018.Pubmed link
  • 110  Quinn AG. Molecular genetics of human non‐melanoma skin cancer. Cancer Surv 1996;26:89114.Pubmed link
  • 111  Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell naevus syndrome. Science 1996;272:166871.Cross Ref linkPubmed link
  • 112  Bale AE, Gailani MR, Leffell DJ. The Gorlin syndrome gene: a tumor suppressor active in basal cell carcinogenesis and embryonic development. Proc Assoc Am Phys 1995;107:2537.Pubmed link
  • 113  Soufir N, Gerard B, Portela M, et al. PTCH mutations and deletions in patients with typical nevoid basal cell carcinoma syndrome and in patients with a suspected genetic predisposition to basal cell carcinoma: a French study. Br J Cancer 2006;95:54853.Cross Ref linkPubmed link
  • 114  Nowakowska B, Kutkowska‐Kazmierczak A, Stankiewicz P, et al. A girl with deletion 9q22.1‐q22.32 including the PTCH and ROR2 genes identified by genome‐wide array‐CGH. Am J Med Genet A 2007;143:18859.Cross Ref link
  • 115  Olivieri C, Maraschio P, Caselli D, et al. Interstitial deletion of chromosome 9, int del(9)(9q22.31‐q31.2), including the genes causing multiple basal cell nevus syndrome and Robinow/brachydactyly 1 syndrome. Eur J Pediatr 2003;162:1003.Pubmed link
  • 116  Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 1997;69:299308.Cross Ref linkPubmed link
  • 117  Southwick GJ, Schwartz RA. The basal cell naevus syndrome: disasters occurring among a series of 36 patients. Cancer 1979;44:2294305.Cross Ref linkPubmed link
  • 118  Wilson LC, Ajayi‐Obe E, Bernhard B, et al. Patched mutations and hairy skin patches: a new sign in Gorlin syndrome. Am J Med Genet A 2006;140:262530.Cross Ref linkPubmed link
  • 119  Gorlin RJ. The naevoid basal cell carcinoma syndrome. Medicine 1987;66:98113.Cross Ref linkPubmed link
  • 120  Binkley GW, Johnson HH. Epithelioma adenoides cysticum: basal cell naevi, agenesis of the corpus callosum and dental cysts. Arch Dermatol 1951;63:7384.
  • 121  Anderson DE, Taylor WB, Falls MF, et al. The naevoid basal cell carcinoma syndrome. Am J Hum Genet 1967;19:1222.Pubmed link
  • 122  Berlin NI, van Scott EJ, Clendenning WE, et al. Basal cell naevus syndrome: combined clinical staff conference at the National Institute of Health. Ann Intern Med 1966;64:40321.Cross Ref linkPubmed link
  • 123  Clendenning WE, Block JB, Radde IC. Basal cell naevus syndrome. Arch Dermatol 1964;90:3853.Cross Ref linkPubmed link
  • 124  Gorlin RJ, Goltz RW. Multiple naevoid basal‐cell epithelioma, jaw cysts and bifid rib: a syndrome. N Engl J Med 1960;262:90812.Cross Ref linkPubmed link
  • 125  Gorlin RJ, Yunis JJ, Tuna N. Multiple naevoid basal cell carcinoma, odontogenic keratocysts and skeletal anomalies: a syndrome. Acta Derm Venereol (Stockh) 1963;43:3955.
  • 126  Howell JB, Caro MR. The basal‐cell naevus: its relationship to multiple cutaneous cancers and associated anomalies of development. AMA Arch Dermatol 1959;79:6780.Cross Ref link
  • 127  Van Dijk E, Sanderink JFH. Basal cell naevus syndrome. Dermatologica 1967;134:1016.Cross Ref link
  • 128  Evans DG, Farndon PA, Burnell LD, et al. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer 1991;64:95961.Cross Ref linkPubmed link
  • 129  Nagy K, Kiss E, Erdei C, et al. Complex care by multiple medical and dental specialists of a patient with aggressive Gorlin–Goltz syndrome. Postgrad Med J 2008;84:3302.Cross Ref linkPubmed link
  • 130  Goette DK. Topical chemotherapy with 5‐fluorouracil: a review. J Am Acad Dermatol 1981;4:63349.Cross Ref linkPubmed link
  • 131  Micali G, De Pasquale R, Caltabiano R, et al. Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell naevus syndrome: a preliminary report. J Dermatol Treat 2002;13:1237.Cross Ref link
  • 132  Goldberg LH, Rubin HA. Management of basal cell carcinoma: which option is best? Postgrad Med 1989;85:57–8,613.
  • 133  Cristofolini M, Zumiani G, Scappini P, Piscioli F. Aromatic retinoid in the chemoprevention of the progression of naevoid basal‐cell carcinoma syndrome. J Dermatol Surg Oncol 1984;10:77881.Cross Ref linkPubmed link
  • 134  Tang JY, Mackay‐Wiggan JM, Aszterbaum M, et al. Inhibiting the Hedgehog pathway in patients with the basal‐cell nevus syndrome. N Engl J Med 2012;366:2180218.Cross Ref linkPubmed link
  • 135  Lear JT. Oral Hedgehog‐pathway inhibitors for basal‐cell carcinoma. N Engl J Med 2012;366:22256.Cross Ref linkPubmed link
  • 136  Kiwilsza M, Sporniak‐Tutak K. Gorlin–Goltz syndrome – a medical condition requiring a multidisciplinary approach. Med Sci Monit 2012;18:RA14553.Cross Ref linkPubmed link

Bazex–Dupré–Christol syndrome

  • 137  Vabres P, Lacombe D, Rabinowitz LG, et al. The gene for Bazex–Dupré–Christol syndrome maps to chromosome Xq. J Invest Dermatol 1995;105:8791.Cross Ref linkPubmed link
  • 138  Parren LJ, Abuzahra F, Wagenvoort T, et al. Linkage refinement of Bazex–Dupré–Christol syndrome to an 11·4‐Mb interval on chromosome Xq25‐27.1. Br J Dermatol 2011;165:2013.Cross Ref linkPubmed link
  • 139  Bazex A, Dupré A, Christol B. Atrophodermie folliculaire proliférations baso‐cellulaires et hypotrichose. Ann Dermatol Syphiligr 1966;93:24154.
  • 140  Abuzahra F1, Parren LJ, Frank J. Multiple familial and pigmented basal cell carcinomas in early childhood – Bazex–Dupré–Christol syndrome. J Eur Acad Dermatol Venereol 2012;26:11721.Cross Ref linkPubmed link
  • 141  Vabres P, Lacombe D, Rabinowitz LG, et al. The gene for Bazex–Dupré–Christol syndrome maps to chromosome Xq. J Invest Dermatol 1995;105:8791.Cross Ref linkPubmed link